MYC is among the most frequently overexpressed oncogenes in human cancers, and preclinical studies have shown that BET inhibitors may also have activity in a broader range of tumor types, including mCRPC and CRC.23, 24, 25 Additionally, BET inhibition was shown to reduce SCLC cell proliferation via downregulation of ASCL1 gene expression, providing rationale for the clinical development of BET inhibitors in this disease.26 This evidence concerns the gene DNER and cancer.